{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:16:22Z","timestamp":1786119382820,"version":"build-2736575974"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1097\/fjc.0b013e3181bfb1a2","type":"journal-article","created":{"date-parts":[[2010,1,13]],"date-time":"2010-01-13T02:58:18Z","timestamp":1263351498000},"page":"1-5","source":"Crossref","is-referenced-by-count":28,"title":["Pleiotropic Effects With Equivalent Low-density Lipoprotein Cholesterol Reduction: Comparative Study Between Simvastatin and Simvastatin\/Ezetimibe Coadministration"],"prefix":"10.1097","volume":"55","author":[{"given":"Daniel B","family":"Araujo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo C","family":"Bertolami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waldinai P","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dulcineia S P","family":"Abdalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre A","family":"Faludi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana P","family":"Bricharello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210208","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1001\/jama.1986.03380200061022","article-title":"Is a relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).","volume":"256","author":"Stamler","year":"1986","journal-title":"JAMA"},{"key":"R2-1-20210208","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","article-title":"The Lipid Research Clinics Coronary Primary Prevention Trial results.","volume":"251","year":"1984","journal-title":"JAMA"},{"key":"R3-1-20210208","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1001\/jama.279.20.1615","article-title":"Weis S, et al; for the AFCAPS\/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS\/TexCAPS.","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"R4-1-20210208","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary artery heart disease. The Scandinavian Simvastatin Survival Study (4S).","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"R5-1-20210208","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"R6-1-20210208","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/01.mol.0000236368.42755.25","article-title":"Statins: are any questions unanswered?","volume":"17","author":"Kearney","year":"2006","journal-title":"Curr Opin Lipidol"},{"key":"R7-1-20210208","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/01.mol.0000191913.16321.60","article-title":"Clinical implications for statin pleiotropy.","volume":"16","author":"Liao","year":"2005","journal-title":"Curr Opin Lipidol"},{"key":"R8-1-20210208","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0021-9150(02)00374-X","article-title":"Electronegative LDL of FH subjects: chemical characterization and induction of chemokine release from human endothelial cells.","volume":"166","author":"Sanchez-Quesada","year":"2003","journal-title":"Atherosclerosis"},{"key":"R9-1-20210208","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.amjcard.2003.08.048","article-title":"Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein.","volume":"92","author":"Sager","year":"2003","journal-title":"Am J Cardiol"},{"key":"R10-1-20210208","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/S0002-9149(02)02774-1","article-title":"Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia.","volume":"90","author":"Gagne","year":"2002","journal-title":"Am J Cardiol"},{"key":"R11-1-20210208","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1161\/01.CIR.0000164260.82417.3F","article-title":"Simvastatin versus ezetimibe pleiotropic and lipid-lowering effects on endothelial function in humans.","volume":"111","author":"Landmesser","year":"2005","journal-title":"Circulation"},{"key":"R12-1-20210208","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/S0002-9149(02)02798-4","article-title":"Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia.","volume":"90","author":"Dujovne","year":"2002","journal-title":"Am J Cardiol"},{"key":"R13-1-20210208","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/00041433-200312000-00015","article-title":"Therapy and clinical trials: ezetimibe.","volume":"14","author":"Ishwarlau","year":"2003","journal-title":"Curr Opin Lipidol"},{"key":"R14-1-20210208","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use the preparative ultracentrifuge.","volume":"18","author":"Friedwald","year":"1972","journal-title":"Clin Chem"},{"key":"R15-1-20210208","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/0140-6736(92)93147-F","article-title":"Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis.","volume":"340","author":"Celermajer","year":"1992","journal-title":"Lancet"},{"key":"R18-1-20210208","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0735-1097(01)01746-6","article-title":"Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery.","volume":"39","author":"Corretti","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"R19-1-20210208","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0195-668X(02)00803-5","article-title":"Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.","volume":"24","author":"Melani","year":"2003","journal-title":"Eur Heart J"},{"key":"R20-1-20210208","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMoa0800742","article-title":"Stroes ESG, et al; for the ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia.","volume":"358","author":"Kastelein","year":"2008","journal-title":"N Engl J Med"},{"key":"R21-1-20210208","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1161\/01.ATV.0000032033.39301.6A","article-title":"Statin therapy in acute coronary syndromes. Mechanistic Insight Into Clinical Benefit.","volume":"22","author":"Sposito","year":"2002","journal-title":"Arterioscler Tromb Vasc"},{"key":"R22-1-20210208","first-page":"139","article-title":"Immunomodulatory effects of HMG-CoA reductase inhibitors.","volume":"51","author":"Danesh","year":"2003","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"R23-1-20210208","doi-asserted-by":"crossref","first-page":"520","DOI":"10.7326\/0003-4819-145-7-200610030-00010","article-title":"Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem.","volume":"145","author":"Hayward","year":"2006","journal-title":"Ann Intern Med"},{"key":"R24-1-20210208","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ahj.2004.11.023","article-title":"Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the vytorin versus atorvastatin (VYVA) study.","volume":"149","author":"Ballantyne","year":"2005","journal-title":"Am Heart J"},{"key":"R25-1-20210208","doi-asserted-by":"crossref","first-page":"620","DOI":"10.4065\/79.5.620","article-title":"Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial.","volume":"79","author":"Goldberg","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"R26-1-20210208","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0735-1097(02)02610-4","article-title":"Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia.","volume":"40","author":"Davidson","year":"2002","journal-title":"Am Coll Cardiol"},{"key":"R27-1-20210208","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1046\/j.1365-2125.2002.01633.x","article-title":"Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin.","volume":"54","author":"Kosoglou","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"R28-1-20210208","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/0140-6736(93)90634-S","article-title":"Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients.","volume":"341","author":"Leung","year":"1993","journal-title":"Lancet"},{"key":"R29-1-20210208","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1161\/01.RES.0000099503.13312.7B","article-title":"Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function.","volume":"93","author":"Wassmann","year":"2003","journal-title":"Circ Res"},{"key":"R30-1-20210208","first-page":"1713","article-title":"Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease.","volume":"1711-","author":"Settergren","year":"2008","journal-title":"Eur Heart J"},{"key":"R31-1-20210208","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.amjcard.2006.10.022","article-title":"Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study).","volume":"99","author":"Ballantyne","year":"2007","journal-title":"Am J Cardiol"},{"key":"R32-1-20210208","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jacc.2006.10.064","article-title":"Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?","volume":"49","author":"Piorkowski","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R33-1-20210208","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0021-9150(02)00316-7","article-title":"Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus.","volume":"166","author":"Van de Ree","year":"2003","journal-title":"Atherosclerosis"},{"key":"R34-1-20210208","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/clc.4960270405","article-title":"Effects of conventional and aggressive statin treatment on markers of endothelial function and inflammation.","volume":"27","author":"Hognestad","year":"2004","journal-title":"Clin Cardiol"},{"key":"R35-1-20210208","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMoa0800742","article-title":"Simvastatin with or without ezetimibe in familial hypercholesterolemia.","volume":"358","author":"Kastelein","year":"2008","journal-title":"N Engl J Med"},{"key":"R36-1-20210208","first-page":"1343","article-title":"Boman K, et al; for the SEAS Investigators.","volume":"359","author":"Rossebo","year":"2008","journal-title":"New engl J med"},{"key":"R37-1-20210208","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1016\/j.jacc.2008.10.031","article-title":"Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes the stop atherosclerosis in native diabetics study trial.","volume":"52","author":"Fleg","year":"2008","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Cardiovascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00005344-201001000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:10:26Z","timestamp":1786039826000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005344-201001000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/fjc.0b013e3181bfb1a2","relation":{},"ISSN":["0160-2446"],"issn-type":[{"value":"0160-2446","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}